Show simple item record

dc.contributor.authorHanly, John G
dc.contributor.authorUrowitz, Murray B
dc.contributor.authorSu, Li
dc.contributor.authorGordon, Caroline
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorSanchez-Guerrero, Jorge
dc.contributor.authorRomero-Diaz, Juanita
dc.contributor.authorWallace, Daniel J
dc.contributor.authorClarke, Ann E
dc.contributor.authorGinzler, Em
dc.contributor.authorMerrill, Joan T
dc.contributor.authorIsenberg, David A
dc.contributor.authorRahman, Anisur
dc.contributor.authorPetri, M
dc.contributor.authorFortin, Paul R
dc.contributor.authorGladman, Dd
dc.contributor.authorBruce, Ian N
dc.contributor.authorSteinsson, Kristjan
dc.contributor.authorDooley, Ma
dc.contributor.authorKhamashta, Munther A
dc.contributor.authorAlarcón, Graciela S
dc.contributor.authorFessler, Barri J
dc.contributor.authorRamsey-Goldman, Rosalind
dc.contributor.authorManzi, Susan
dc.contributor.authorZoma, Asad A
dc.contributor.authorSturfelt, Gunnar K
dc.contributor.authorNived, Ola
dc.contributor.authorAranow, Cynthia
dc.contributor.authorMackay, Meggan
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorvan Vollenhoven, Rf
dc.contributor.authorKalunian, Kenneth C
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorLim, Sam
dc.contributor.authorKamen, Diane L
dc.contributor.authorPeschken, Christine A
dc.contributor.authorInanc, Murat
dc.contributor.authorTheriault, Chris
dc.contributor.authorThompson, Kara
dc.contributor.authorFarewell, Vernon
dc.date.accessioned2023-02-06T20:11:13Z
dc.date.available2023-02-06T20:11:13Z
dc.date.issued2012-04-04
dc.identifier.citationHanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler E, Merrill JT, Isenberg DA, Rahman A, Petri M, Fortin PR, Gladman D, Bruce IN, Steinsson K, Dooley M, Khamashta MA, Alarcón GS, Fessler BJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven R, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Theriault C, Thompson K, Farewell V. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012 Sep;71(9):1502-9. doi: 10.1136/annrheumdis-2011-201089. Epub 2012 Apr 4. PMID: 22492779; PMCID: PMC4656036.en_US
dc.identifier.eissn1468-2060
dc.identifier.doi10.1136/annrheumdis-2011-201089
dc.identifier.pmid22492779
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8253
dc.description.abstractThe aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE).
dc.description.abstractThe Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β(2) glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions.
dc.description.abstractThe cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p<0.01). Higher damage scores (without neuropsychiatric variables) were associated with an increased risk of subsequent seizures (SDI=1:3.93 (1.46 to 10.55); SDI=2 or 3:1.57 (0.32 to 7.65); SDI≥4:7.86 (0.89 to 69.06); p=0.03). There was an association with disease activity but not with autoantibodies. Seizures attributed to SLE frequently resolved (59/78 (76%)) in the absence of antiseizure drugs. There was no significant impact on the mental component summary or physical component summary scores. Antimalarial drugs in the absence of immunosuppressive agents were associated with reduced seizure risk (0.07 (0.01 to 0.66); p=0.03).
dc.description.abstractSeizures occurred close to SLE diagnosis, in patients with African race/ethnicity, lower educational status and cumulative organ damage. Most seizures resolved without a negative impact on health-related quality of life. Antimalarial drugs were associated with a protective effect.
dc.language.isoenen_US
dc.relation.urlhttps://ard.bmj.com/content/71/9/1502.longen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSeizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAnnals of the rheumatic diseasesen_US
dc.source.volume71
dc.source.issue9
dc.source.beginpage1502
dc.source.endpage9
dc.source.countryCanada
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryCanada
dc.source.countryCanada
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryEngland
dc.description.versionAMen_US
refterms.dateFOA2023-02-06T20:11:13Z
html.description.abstractThe aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE).
html.description.abstractThe Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β(2) glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions.
html.description.abstractThe cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p<0.01). Higher damage scores (without neuropsychiatric variables) were associated with an increased risk of subsequent seizures (SDI=1:3.93 (1.46 to 10.55); SDI=2 or 3:1.57 (0.32 to 7.65); SDI≥4:7.86 (0.89 to 69.06); p=0.03). There was an association with disease activity but not with autoantibodies. Seizures attributed to SLE frequently resolved (59/78 (76%)) in the absence of antiseizure drugs. There was no significant impact on the mental component summary or physical component summary scores. Antimalarial drugs in the absence of immunosuppressive agents were associated with reduced seizure risk (0.07 (0.01 to 0.66); p=0.03).
html.description.abstractSeizures occurred close to SLE diagnosis, in patients with African race/ethnicity, lower educational status and cumulative organ damage. Most seizures resolved without a negative impact on health-related quality of life. Antimalarial drugs were associated with a protective effect.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAnnals of the rheumatic diseases


Files in this item

Thumbnail
Name:
nihms5144.pdf
Size:
496.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International